An interventional study of Biospecimen Collection in Hemophilia A, sponsored by BioMarin Pharmaceutical. Terminated at 18 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-19.
Sponsored by BioMarin Pharmaceutical · Not applicable, Interventional, and Other
A prospective cohort study utilizing biospecimen sample collection from adult Hemophilia A subjects to evaluate and characterize seroprevalence and the seroconversion of antibodies against AAV serotypes
This is a multinational, multi-center, prospective cohort study utilizing biospecimen sample collection from adult Hemophilia A subjects to evaluate and characterize seroprevalence and the seroconversion of antibodies against AAV serotypes
866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
This study's enrollment of 321 is above the median of 28 across 512 interventional studies indexed under Hemophilia A.
Browse Hemophilia A studies →BioMarin Pharmaceutical is the lead sponsor of 110 studies on the registry; 13 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
All Patients are within the same arm
Procedure: Biospecimen Collection
Biospecimen Sample Collection
To qunatify Seroprevalence of antibodies to selected AAV serotypes
Number of patients with detectable antibodies to selected AAV serotypes
Time frame: 52 weeks
To describe and characterize selected AAV serotypes antibody responses in adult subjects with Hemophilia A
Antibody titer levels measured in target population to selected AAV serotypes
Time frame: 52 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioMarin Pharmaceutical